Sixty‐nine consecutive patients with primary refractory DLBCL who were treated at our institution were clinicopathologically analyzed.We identified a subgroup of patients with primary refractory DLBCL, including primary progressors (no response to R‐CHOP) or those with the double expression of MYC and BCL2, who may not benefit from current treatment strategies.Further treatment development is needed to improve the outcomes of these patients. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.